本文来自方正证券研究所于2025年5月23日发布的报告《云顶新耀(01952):肾科大单品进入医保放量,多领域创新药进入收获期》,欲了解具体内容,请阅读报告原文。周超泽 S1220523070003许 睿 S1220523080005李霁阳 S1220525050004核心观点耐赋康纳入医保,公司发展进入新阶段。云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造及商业化的全产业链综合性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.